Quilostigmine

Quilostigmine, also known as NXX-066, is an acetylcholinesterase inhibitor. Its structure is related to that of physostigmine, another acetylcholinesterase inhibitor.

Biological activity

Quilostigmine displays inhibition of the AChE enzyme with an value of 0.148 µM.

History

Quilostigmine was initially studied by AstraZeneca for the treatment of Alzheimer's disease; however, the drug appears to have been discontinued, reaching a maximum trial phase of two.